1. Home
  2. ADPT vs JBI Comparison

ADPT vs JBI Comparison

Compare ADPT & JBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • JBI
  • Stock Information
  • Founded
  • ADPT 2009
  • JBI 2002
  • Country
  • ADPT United States
  • JBI United States
  • Employees
  • ADPT N/A
  • JBI N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • JBI Building Products
  • Sector
  • ADPT Health Care
  • JBI Industrials
  • Exchange
  • ADPT Nasdaq
  • JBI Nasdaq
  • Market Cap
  • ADPT 1.1B
  • JBI 924.6M
  • IPO Year
  • ADPT 2019
  • JBI N/A
  • Fundamental
  • Price
  • ADPT $9.03
  • JBI $8.20
  • Analyst Decision
  • ADPT Buy
  • JBI Buy
  • Analyst Count
  • ADPT 6
  • JBI 6
  • Target Price
  • ADPT $9.83
  • JBI $9.80
  • AVG Volume (30 Days)
  • ADPT 3.0M
  • JBI 1.2M
  • Earning Date
  • ADPT 05-01-2025
  • JBI 05-08-2025
  • Dividend Yield
  • ADPT N/A
  • JBI N/A
  • EPS Growth
  • ADPT N/A
  • JBI N/A
  • EPS
  • ADPT N/A
  • JBI 0.35
  • Revenue
  • ADPT $189,527,000.00
  • JBI $919,800,000.00
  • Revenue This Year
  • ADPT $21.20
  • JBI N/A
  • Revenue Next Year
  • ADPT $21.99
  • JBI $7.08
  • P/E Ratio
  • ADPT N/A
  • JBI $23.38
  • Revenue Growth
  • ADPT 8.61
  • JBI N/A
  • 52 Week Low
  • ADPT $2.99
  • JBI $6.05
  • 52 Week High
  • ADPT $10.28
  • JBI $15.35
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 57.82
  • JBI 70.43
  • Support Level
  • ADPT $8.38
  • JBI $7.09
  • Resistance Level
  • ADPT $9.51
  • JBI $7.43
  • Average True Range (ATR)
  • ADPT 0.66
  • JBI 0.23
  • MACD
  • ADPT 0.16
  • JBI 0.18
  • Stochastic Oscillator
  • ADPT 63.02
  • JBI 93.05

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About JBI Janus International Group Inc.

Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.

Share on Social Networks: